Phreesia, Inc. (PHR) Stock Analysis and Metrics

Sector: Healthcare Industry: Health Information Services CIK: 0001412408

Market Cap 551.98 Mn

P/E 308.00

P/S 1.15

Div. Yield 0.00

ROIC (Qtr) 0.00

Total Debt (Qtr) 100.09 Mn

Revenue Growth (1y) (Qtr) 15.85

Add ratio to table...

About

Phreesia, Inc. was founded in 2005 and completed its initial public offering in July 2019. The company provides an integrated software payments and engagement platform designed to address three foundational challenges in healthcare delivery access to care affordability of care and patient health outcomes. Its platform is embedded directly into provider workflows and patient interactions enabling healthcare organizations to activate patients streamline administrative processes and improve financial performance across the care continuum. Phreesia...

Phreesia, Inc. was founded in 2005 and completed its initial public offering in July 2019. The company provides an integrated software payments and engagement platform designed to address three foundational challenges in healthcare delivery access to care affordability of care and patient health outcomes. Its platform is embedded directly into provider workflows and patient interactions enabling healthcare organizations to activate patients streamline administrative processes and improve financial performance across the care continuum. Phreesia serves a diverse group of healthcare organizations including ambulatory practices health systems and hospitals as well as life sciences companies government entities patient advocacy public interest and not for profit and other organizations. Its solutions support the patient journey from care discovery and scheduling through intake payment and post visit follow up. In fiscal year 2026 the platform facilitated approximately 180 million patient visits representing about one in six ambulatory patient visits in the United States. During fiscal year 2026 Phreesia completed the acquisition of AccessOne Parent Holdings Inc expanding its addressable market for healthcare payments and offering a trusted scalable compliant and operationally efficient healthcare payment card that accelerates cash flow for providers.

Phreesia generates revenue through a diversified model that includes three revenue streams subscription and related services payment solutions and Network Solutions. Subscription and related services revenue is derived from recurring subscription fees and related services and remains relatively consistent throughout the fiscal year due to the recurring nature of contracts. Payment solutions revenue comprises payment processing fees and financing fees and tends to be higher during the first two to three months of the calendar year driven in part by the resetting of patient deductibles. Network Solutions revenue is generated through annual contracts priced on a per engagement basis supported by closed loop reporting and third party measurement and is typically higher in the second half of the fiscal year reflecting life sciences marketing budget cycles. The company's business model provides meaningful visibility into future revenue as a large portion of revenue comes from recurring and re occurring streams.

The company operates through the following segments Subscription and Related Services Payment Solutions and Network Solutions.

• The Subscription and Related Services segment provides the core software platform that enables patient self scheduling appointment optimization referral management and AI powered communication tools. It also includes digital intake clinical data capture patient engagement activation tools and measurement and analytics solutions that support care delivery across the continuum. Revenue in this segment is primarily derived from recurring subscription fees charged to healthcare organizations for access to the platform and related services.

• The Payment Solutions segment offers integrated payment processing financing and a proprietary healthcare payment card that streamlines patient payments and improves provider cash flow. It includes eligibility and cost transparency tools embedded in intake and post visit workflows as well as financing solutions that give patients flexible payment options while helping providers accelerate collections. Revenue in this segment comes from payment processing fees financing fees and transaction based charges tied to the volume of payments processed through the platform.

• The Network Solutions segment provides a channel for life sciences companies and other organizations to deliver compliant personalized engagement to patients and providers who use Phreesia's solutions. It operates through annual contracts priced on a per engagement basis and includes closed loop reporting third party measurement and analytics to assess campaign effectiveness. Revenue in this segment is generated from these annual engagements and tends to be higher in the second half of the fiscal year aligning with life sciences marketing budget cycles.

Phreesia competes in a rapidly evolving healthcare technology market that includes point solution providers and broader platform vendors. The company faces competition from established vendors that offer individual products for scheduling payments or patient engagement as well as newer entrants that incorporate artificial intelligence into similar workflows. Phreesia believes it differentiates itself through the breadth of its integrated platform the depth of its interoperability with major electronic health record and practice management systems the scale of its provider and patient network its compliance first approach to engagement and its ability to deliver measurable value to customers. These factors enable the company to win and retain clients across ambulatory practices health systems hospitals and life sciences organizations.

Phreesia serves a broad customer base that includes ambulatory medical practices health systems hospitals life sciences companies government agencies patient advocacy groups public interest organizations and not for profit entities. The company does not disclose specific customer names in its filing but indicates that its solutions are used by a wide range of healthcare stakeholders involved in the patient journey. This diverse base supports the platform's network effects and contributes to the stability of its recurring revenue streams.

Investment thesis

Bull case

Phreesia’s first ever net income positive quarter signals a shift in profitability that the market has not fully priced in. The company posted $700,000 GAAP net income and $22 million Adjusted EBITDA, up $16 million year over year, a margin that rose to 19%. The jump is driven by disciplined cost management, as operating expenses fell relative to revenue growth, and by a 15% increase in total revenue to $117.3 million. This milestone underlines a scalable business model that can translate incremental growth into real earnings, setting the stage for sustained profitability.
The AccessOne acquisition is a strategic bolt that expands Phreesia’s addressable market by $6 billion in payments and an additional $6 billion in network solutions. AccessOne’s portfolio of $450 million in receivables and its footprint in the largest health systems provides an immediate revenue boost of $35 million and an Adjusted EBITDA contribution of $11 million once the transaction closes. Integration of AccessOne’s payment plan platform dovetails with Phreesia’s existing patient activation tools, creating cross‑sell opportunities that increase the value of each health system relationship. By adding this new revenue stream, the company is poised to lift its 2026 outlook and accelerate margin expansion beyond the current Adjusted EBITDA range.
Phreesia’s AI offerings, particularly Voice AI, have moved from internal experimentation to monetized external products. Management indicates that the Voice AI tool is already generating incremental revenue, with usage that drives higher patient engagement and reduces provider call‑center load. The ability to monetize AI features without a significant cost‑to‑serve component is a competitive moat that can raise per‑client revenue while maintaining low variable costs. As AI adoption in healthcare accelerates, Phreesia is positioned to capture early market share and set pricing expectations that reflect true value to providers.
Network solutions have grown 25% YoY, driven by higher campaign volume and new life‑science partnerships. The company’s network solutions segment contributed $35 million in revenue, up from $28 million, and its TAM expansion adds an estimated $6 billion. By extending its platform into marketing and patient outreach, Phreesia taps into a high‑margin revenue source that is less sensitive to payment‑processing cycles. The scaling of this segment indicates a robust pipeline of marketing spend from pharmaceutical and biotechnology firms, which should translate into a steady revenue per client growth.
Patient payment volume has risen 13% to $1.18 billion, with the payment facilitator share at 85%. A high payment facilitator percentage signals strong adoption of Phreesia’s integrated payment gateway, which boosts fee‑based revenue and provides a recurring revenue source. As healthcare costs shift more toward patients, this payment volume trend reinforces the company’s core product proposition and creates a lock‑in effect that discourages churn. The growing payment volume aligns with the company’s trajectory toward higher average revenue per healthcare services client.

Phreesia’s first ever net income positive quarter signals a shift in profitability that the market has not fully priced in. The company posted $700,000 GAAP net income and $22 million Adjusted EBITDA, up $16 million year over year, a margin that rose to 19%. The jump is driven by disciplined cost management, as operating expenses fell relative to revenue growth, and by a 15% increase in total revenue to $117.3 million. This milestone underlines a scalable business model that can translate incremental growth into real earnings, setting the stage for sustained profitability.
The AccessOne acquisition is a strategic bolt that expands Phreesia’s addressable market by $6 billion in payments and an additional $6 billion in network solutions. AccessOne’s portfolio of $450 million in receivables and its footprint in the largest health systems provides an immediate revenue boost of $35 million and an Adjusted EBITDA contribution of $11 million once the transaction closes. Integration of AccessOne’s payment plan platform dovetails with Phreesia’s existing patient activation tools, creating cross‑sell opportunities that increase the value of each health system relationship. By adding this new revenue stream, the company is poised to lift its 2026 outlook and accelerate margin expansion beyond the current Adjusted EBITDA range.
Phreesia’s AI offerings, particularly Voice AI, have moved from internal experimentation to monetized external products. Management indicates that the Voice AI tool is already generating incremental revenue, with usage that drives higher patient engagement and reduces provider call‑center load. The ability to monetize AI features without a significant cost‑to‑serve component is a competitive moat that can raise per‑client revenue while maintaining low variable costs. As AI adoption in healthcare accelerates, Phreesia is positioned to capture early market share and set pricing expectations that reflect true value to providers.
Network solutions have grown 25% YoY, driven by higher campaign volume and new life‑science partnerships. The company’s network solutions segment contributed $35 million in revenue, up from $28 million, and its TAM expansion adds an estimated $6 billion. By extending its platform into marketing and patient outreach, Phreesia taps into a high‑margin revenue source that is less sensitive to payment‑processing cycles. The scaling of this segment indicates a robust pipeline of marketing spend from pharmaceutical and biotechnology firms, which should translate into a steady revenue per client growth.
Patient payment volume has risen 13% to $1.18 billion, with the payment facilitator share at 85%. A high payment facilitator percentage signals strong adoption of Phreesia’s integrated payment gateway, which boosts fee‑based revenue and provides a recurring revenue source. As healthcare costs shift more toward patients, this payment volume trend reinforces the company’s core product proposition and creates a lock‑in effect that discourages churn. The growing payment volume aligns with the company’s trajectory toward higher average revenue per healthcare services client.

Bear case

Integration of AccessOne presents a significant risk that may dilute the expected upside. The company has not yet proven the ability to merge payment‑plan technology with its existing platform, and integration costs could be higher than projected. Any delay or inefficiency in closing the acquisition would postpone the $35 million annual revenue contribution and the $11 million Adjusted EBITDA lift. This uncertainty could lead to missed guidance and erode investor confidence.
Management’s statements that “Phreesia is not the risk bearer” in the AccessOne relationship obscure the fact that the company still faces indirect credit exposure. While the payment plan risk is carried by a bank and providers, default or regulatory changes in the payment‑plan market could affect the value of the receivables and reduce expected revenue. Such indirect exposure could materialize as a revenue shortfall, undermining the projected gains from the acquisition.
The company’s reliance on external‑facing AI products carries a potential technology risk. Although Voice AI is monetized today, its long‑term viability depends on continuous improvement and competitive differentiation. Larger technology vendors are entering the AI‑driven patient engagement space, which could erode Phreesia’s market share and pricing power. If the AI features fail to sustain adoption, the company’s high development costs could become stranded assets.
Phreesia’s sales and marketing expenses grew to $25.4 million in Q2, up from $30.2 million the prior quarter, yet the company remains far from breakeven. The high cost base relative to revenue signals inefficiencies that could intensify if growth stalls. If the company cannot reduce its sales and marketing spend without sacrificing customer acquisition, margin expansion will be limited. The ongoing burn on this front introduces a downside risk to profitability forecasts.
The company’s total revenue per AHSC, while increasing, remains modest at $26,249 in Q2. The incremental revenue per client is largely driven by a few large accounts, which makes the company susceptible to concentration risk. A loss of one or two key health‑system clients could materially reduce revenue, affecting both top‑line growth and the ability to service debt. This concentration risk is not fully reflected in the current guidance.

Integration of AccessOne presents a significant risk that may dilute the expected upside. The company has not yet proven the ability to merge payment‑plan technology with its existing platform, and integration costs could be higher than projected. Any delay or inefficiency in closing the acquisition would postpone the $35 million annual revenue contribution and the $11 million Adjusted EBITDA lift. This uncertainty could lead to missed guidance and erode investor confidence.
Management’s statements that “Phreesia is not the risk bearer” in the AccessOne relationship obscure the fact that the company still faces indirect credit exposure. While the payment plan risk is carried by a bank and providers, default or regulatory changes in the payment‑plan market could affect the value of the receivables and reduce expected revenue. Such indirect exposure could materialize as a revenue shortfall, undermining the projected gains from the acquisition.
The company’s reliance on external‑facing AI products carries a potential technology risk. Although Voice AI is monetized today, its long‑term viability depends on continuous improvement and competitive differentiation. Larger technology vendors are entering the AI‑driven patient engagement space, which could erode Phreesia’s market share and pricing power. If the AI features fail to sustain adoption, the company’s high development costs could become stranded assets.
Phreesia’s sales and marketing expenses grew to $25.4 million in Q2, up from $30.2 million the prior quarter, yet the company remains far from breakeven. The high cost base relative to revenue signals inefficiencies that could intensify if growth stalls. If the company cannot reduce its sales and marketing spend without sacrificing customer acquisition, margin expansion will be limited. The ongoing burn on this front introduces a downside risk to profitability forecasts.
The company’s total revenue per AHSC, while increasing, remains modest at $26,249 in Q2. The incremental revenue per client is largely driven by a few large accounts, which makes the company susceptible to concentration risk. A loss of one or two key health‑system clients could materially reduce revenue, affecting both top‑line growth and the ability to service debt. This concentration risk is not fully reflected in the current guidance.

Segments Breakdown of Revenue (2026)

Equity Components Breakdown of Revenue (2026)

Peer comparison

Companies in the Health Information Services

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	GEHC	GE HealthCare Technologies Inc.	28.30 Bn	14.85	1.35	10.13 Bn
2	VEEV	Veeva Systems Inc	25.58 Bn	28.11	8.01	-
3	BTSG	BrightSpring Health Services, Inc.	11.57 Bn	54.88	0.85	2.50 Bn
4	HQY	Healthequity, Inc.	7.08 Bn	33.00	5.39	0.96 Bn
5	DOCS	Doximity, Inc.	4.41 Bn	18.51	6.91	-
6	WAY	Waystar Holding Corp.	3.58 Bn	26.69	3.10	1.47 Bn
7	HNGE	Hinge Health, Inc.	2.95 Bn	-6.00	5.07	-
8	PRVA	Privia Health Group, Inc.	2.76 Bn	118.95	1.30	-

Research Tools

Phreesia, Inc. (NYSE: PHR)

About

Investment thesis

Bull case

Bear case

Segments Breakdown of Revenue (2026)

Equity Components Breakdown of Revenue (2026)

Peer comparison

Research Tools

Phreesia, Inc. (NYSE: PHR)

About

Investment thesis

Bull case

Bear case

Segments Breakdown of Revenue (2026)

Equity Components Breakdown of Revenue (2026)

Peer comparison

Create an account

Sign In

Reset Password